Showing results (81-90 of 127) with videos related to
Sort By:
Pageof 13
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.Journal of Gastroenterology and Hepatology|August 12, 2004
Practical difficulties in the management of hepatitis B in the Asia-Pacific regionRosmawati Mohamed, Paul Desmond, Dong-Jin Suh, et al.Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2020
Efficacy and safety of glecaprevir/pibrentasvir in patients with HCV genotype 5/6: An integrated analysis of phase 2/3 studiesBetty B Yao, Linda M Fredrick, Gretja Schnell, et al.Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2014
Tenofovir disoproxil fumarate in Asian or Pacific Islander chronic hepatitis B patients with high viral load (≥ 9 log10 copies/ml)Scott Fung, Stuart C Gordon, Zahary Krastev, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 30, 2019
Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver DiseaseEdward Gane, Fred Poordad, Neddie Zadeikis, et al.Scientific Reports|July 21, 2019
Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patientsOndrej Podlaha, Edward Gane, Maurizia Brunetto, et al.The Lancet. Gastroenterology & Hepatology|April 14, 2017
Management of hepatitis C virus infection in the Asia-Pacific region: an updateSeng Gee Lim, Alessio Aghemo, Pei-Jer Chen, et al.Gastroenterology|November 5, 2013
Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trialStefan Zeuzem, Thomas Berg, Edward Gane, et al.JCI Insight|May 8, 2020
Development of an RNAi therapeutic for alpha-1-antitrypsin liver diseaseChristine I Wooddell, Keith Blomenkamp, Ryan M Peterson, et al.Lancet (London, England)|December 4, 2014
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trialEric Lawitz, Edward Gane, Brian Pearlman, et al.Pageof 13